Veloxis Pharmaceuticals A/S (VELO) Release: Final STRATO Clinical Study Data Demonstrates Potential for LCP-TacroTM to Improve Tacrolimus-Induced Tremors
5/20/2013 9:56:48 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the STRATO study demonstrates the potential for LCP-Tacro™ to improve tacrolimus-induced tremors in stable kidney transplant patients. The study, Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO™ (STRATO) clinical trial, was presented at the 13th American Transplant Congress, Abstract #B1022, on Sunday, May 19, 2013 in Seattle.
Help employers find you! Check out all the jobs and post your resume.
comments powered by